PDU NetShelter Switched 9000 Series are server rack mounted PDUs from APC offering switching & greater reliability, manageability, & faster deployment.

APC Rack PDU, 9000 switched, 0U, 17.3kW, 208V, 42 C13 and C15, 6 C19 and C21 sockets. With Industry leading reliability, manageability, and security, APC Switched Rack PDU's provide advanced load management plus on/off outlet level power cycling and ...

Explore Power Distribution products from APC us. Search the Power Distribution Range for high-quality needs!

2023年1月9日 · PD-1 (Programmed cell death-1)是一种抑制 T细胞 活化的受体，是肿瘤免疫治疗的重要靶点。 PD-1在长时间受到刺激的 抗原特异性T细胞 上保持高表达，使其对刺激的反应性较低。 因此，越来越多的研究人员关注 PD-1轴 如何传递抑制信号，从而发现新的治疗靶点。 作为一种抑制性信号机制，PD-1轴控制免疫应答。 阻断PD-1轴已被证明对多种肿瘤具有持久的影响，这证明了PD-1在阻断抗肿瘤免疫中的关键作用。 尽管如此，大多数患者对PD-1单药治疗无应 …

PD-L1 is suggested as a negative regulator of T and B cell, and plays important role in mediating tolerance of lymphocytes to self-antigens. It is also involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PD-1-independent manner.

2022年12月31日 · PD-L1在APC上的表达. 2020年一篇发表在《Sci Transl Med》上的文章分析了3例肿瘤临床病人的DC细胞PD-L1的表达，发现PD-L1在DC细胞上显著的高表达，而PD-1和B7.1则不表现出这种表达特征。 另外一个非常有力PD-L1和APC相关的证据则为：PD-L1的单抗Atezolizumab在肾细胞癌（RCC ...

APC-65119 targets PD-1/CD279 in FC applications and shows reactivity with human samples. Phosphate based buffer with 0.09% sodium azide and 0.1% gelatin, pH 7.2. Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment.

APC anti-mouse CD274 (B7-H1, PD-L1) Antibody - CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily.

Invitrogen Anti-CD279 (PD-1) Monoclonal (J43), eBioscience™, Catalog # 11-9985-82. Tested in Flow Cytometry (Flow) applications. This antibody reacts with Mouse samples. Supplied as 100 µg purified antibody (0.5 mg/mL).

2020年1月21日 · 当前的观点表明一种抑制抗肿瘤免疫反应的关键机制是肿瘤微环境中的癌细胞和抗原呈递细胞（APC）表面上的PD-1配体（即PD-L1或PD-L2，统称为PD-L1/2）上调，PD-1配体与肿瘤浸润CD8+ T细胞表面上的PD-1结合，从而导致这些T细胞不能产生抗肿瘤免疫反应。 利用阻断PD-1或者它的配体的抗体靶向PD-1途径可诱导识别肿瘤新抗原的寡克隆CD8+ T细胞增殖。 因此，就癌症而言，PD-1被认为是效应T细胞的主要抑制剂，然而具体到癌细胞和抗原呈递细胞 …